Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.

Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.

The present invention relates to the use of Afabicin in a method of treating bacterial infections involving biofilm that contains Staphylococcus bacteria, wherein the method comprises administering Afabicin in combination with at least one further agent selected from lipopeptides, glycopeptides and lincosamides, such as Daptomycin and/or Vancomycin to the patient.

The present invention relates to the use of Afabicin in a method of treating bacterial infections involving biofilm that contains Staphylococcus bacteria, wherein the method comprises administering Afabicin in combination with at least one further agent selected from lipopeptides, glycopeptides and lincosamides, such as Daptomycin and/or Vancomycin to the patient.

The present disclosure relates to methods for preventing, ameliorating or treating complications caused by a viral infection (e.g., SARS, SARS-cov2, MERS, Influenza etc.), by administration of an immune response modulating agent (IRMA).

The present disclosure relates to methods for preventing, ameliorating or treating complications caused by a viral infection (e.g., SARS, SARS-cov2, MERS, Influenza etc.), by administration of an immune response modulating agent (IRMA).

The present invention relates to a use of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof for preventing or treating an epidemic RNA viral infectious disease, and more specifically, to a pharmaceutical composition for preventing or treating an epidemic RNA viral infectious disease, in particular, Coronavirus Disease 2019 (COVID-19), the composition comprising a therapeutically effective amount of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.

The present invention relates to a use of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof for preventing or treating an epidemic RNA viral infectious disease, and more specifically, to a pharmaceutical composition for preventing or treating an epidemic RNA viral infectious disease, in particular, Coronavirus Disease 2019 (COVID-19), the composition comprising a therapeutically effective amount of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.

The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure:

##STR00001##

for the treatment and/or prevention of COVID-19 infection. The present disclosure further relates to a pharmaceutical formulation that is administered in the form of dry powder inhalation (DPI) to the subject. The dry powder inhalation formulation comprises a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide, a first lactose, a second lactose, and at least one excipient. The pharmaceutical formulation of the present disclosure increases the bioavailability of the NaDCC, has patient compliance, and reduced adverse effects.

The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure:

##STR00001##

for the treatment and/or prevention of COVID-19 infection. The present disclosure further relates to a pharmaceutical formulation that is administered in the form of dry powder inhalation (DPI) to the subject. The dry powder inhalation formulation comprises a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide, a first lactose, a second lactose, and at least one excipient. The pharmaceutical formulation of the present disclosure increases the bioavailability of the NaDCC, has patient compliance, and reduced adverse effects.